Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

Indical Bioscience – AFOSA portfolio

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.

The Indical Bioscience AFOSA portfolio efficiently identifies companion animal pathogens.

Why choose AFOSA ELISA kits over IFA techniques?

AFOSA has 20 years of experience developing and producing enzyme immunoassays for use in veterinary diagnostics, focusing on the detection of antibodies to parasitic and vector transmitted pathogens.

Although IFA is considered standard for Anaplasma, Ehrlichia and Babesia detection, ELISA is preferred by referral laboratories because it provides:

  • Consistent results while IFA result interpretation is operator dependent.
  • Lower running costs since it can be automated.


Ensure reliable and consistent results through harmonized protocols and reagents on low to high throughput applications.

  • Novel commercial ELISA portfolio, including Babesia and Sarcoptes assays.
  • High performing assays with very good sensitivity and specificity,
    validated by the German authorities (FLI).
  • Harmonized protocols with user-friendly reagents and a flexible microplate
    and reagents system.


View the Indical Bioscience AFOSA brochure

Download the brochure >



Request a Quote

Request Quote

Recent Posts

Healing Eyes with Precision: Research Empowered by Merck’s MILLIPLEX® Technology

Imagine using part of your blood to help heal your eyes A study by Liu et al. (2025) explores a new way to treat corneal neovascularization, a condition…

Read full article

PeptiGrowth – Why use Synthesised Peptide Alternatives to Growth Factors

Advance Your Organoid Research with PeptiGrowth’s PG004 & PG008 Are you striving for consistency, reproducibility, and xeno-free conditions in your organoid cultures? PeptiGrowth is proud to…

Read full article

TriLink – CleanCap® M6 IVT Kit, High Yield

Streamline your mRNA synthesis with TriLink’s CleanCap® IVT kits, which yield up to 1 mg per 100 µL reaction. Designed for efficiency and excellence, these kits include all…

Read full article